Abstract

Novel, single-dose microsphere formulation of azithromycin extendedrelease for the treatment of respiratory tract infections

Author(s): Maya Tatum and Guy W Amsden

This paper reviews the pharmacology, efficacy and safety of the new single-dose azithromycin 2 g extended-release microsphere formulation that has been approved in various countries for the treatment of a variety of upper and lower community-acquired respiratory tract infections. As it has been demonstrated to be at least as effective and safe as valid, contemporary comparators, this new single-dose formulation of azithromycin offers the first treatment option for respiratory tract infections that lends itself to 100% patient compliance and regimen completion.